Protecting yourself against Shingles and pneumococcal disease 26 April 2024 This World Immunisation Week (April 24-30) people living with diabetes are being urged to protect themselves with current immunisations. Examples of two conditions that are important to protect against are Shingles and pneumococcal disease. Herpes zoster, commonly known as Shingles, is a painful infection that occurs when the chickenpox virus reactivates. Shingles can cause severe pain that can last for months. All Australians over 65 years of age are eligible for a free, two-dose course of Shingrix, a safe and effective way to protect against serious diseases caused by shingles. These can include vision loss, pneumonia, hearing problems, brain inflammation or death. The Shingles vaccine is available under the National Immunisation Program. Diabetes Australia member, Margaret Wheatley, 61, has lived with type 1 diabetes for 50 years and urged anyone who is eligible to prioritise getting the Shingles vaccine. “I developed shingles in June last year. The pain is very hard to cope with,” Margaret said. “I knew it was nerve pain, but it started at the top of my head and affected the left side of my face. “I didn’t know what it was, but it was painful. As soon as I found out it was shingles, I went straight to the eye specialist, but my eyes were fine, thank goodness. Some people aren’t that lucky.” Margaret said she would make sure she got her vaccine as soon as the recommended 12 months has passed after she developed the condition. “I will do my best to avoid getting shingles again, that’s for sure.” A vaccine to protect against Pneumococcus is also recommended for people living with diabetes. Diabetes is considered an at-risk condition for invasive pneumococcal disease. Vaccine recommendations and schedules differ depending on age so people should always check with their health professional. It is recommended that all adults with diabetes receive three lifetime doses of pneumococcal polysaccharide vaccine.
News 27 May 2026 Urgent product correction for MiniMed Android App Medtronic and the Therapeutic Goods Administration have issued an Urgent Product Correction for a MiniMed Mobile App Android software version... Continue Reading
News 27 May 2026 Tzield listing a game-changer for early-stage type 1 diabetes The first new therapy for type 1 diabetes in nearly a century, which works to delay the need for insulin therapy in type 1 diabetes, has been approved for use in Australia by the Therapeutic Goods Administration. Continue Reading
Blog 27 May 2026 How diabetes, depression, anxiety, and medicines are connected People with diabetes can be depressed or anxious more often than people without diabetes. Studies show that when you have diabetes, you are almost twice as likely to be depressed, regardless of the type of diabetes. Continue Reading